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REPORT
Congenital Myasthenic Syndrome Type 19
Is Caused by Mutations in COL13A1, Encoding
the Atypical Non-fibrillar Collagen Type XIII a1 Chain
Clare V. Logan,1,11 Judith Cossins,2,11 Pedro M. Rodrı´guez Cruz,2,11 David A. Parry,3 Susan Maxwell,2
Pilar Martı´nez-Martı´nez,4 Joey Riepsaame,5 Zakia A. Abdelhamed,1 Alice V.R. Lake,1 Maria Moran,6
Stephanie Robb,7 Gabriel Chow,6 Caroline Sewry,7 Philip M. Hopkins,8 Eamonn Sheridan,3
Sandeep Jayawant,9 Jacqueline Palace,2,10 Colin A. Johnson,1,* and David Beeson2,*
The neuromuscular junction (NMJ) consists of a tripartite synapse with a presynaptic nerve terminal, Schwann cells that ensheathe the
terminal bouton, and a highly specialized postsynaptic membrane. Synaptic structural integrity is crucial for efficient signal transmis-
sion. Congenital myasthenic syndromes (CMSs) are a heterogeneous group of inherited disorders that result from impaired neuromus-
cular transmission, caused by mutations in genes encoding proteins that are involved in synaptic transmission and in forming and
maintaining the structural integrity of NMJs. To identify further causes of CMSs, we performed whole-exome sequencing (WES) in fam-
ilies without an identified mutation in known CMS-associated genes. In two families affected by a previously undefined CMS, we iden-
tified homozygous loss-of-function mutations in COL13A1, which encodes the alpha chain of an atypical non-fibrillar collagen with a
single transmembrane domain. COL13A1 localized to the human muscle motor endplate. Using CRISPR-Cas9 genome editing,
modeling of the COL13A1 c.1171delG (p.Leu392Sfs*71) frameshift mutation in the C2C12 cell line reduced acetylcholine receptor
(AChR) clustering during myotube differentiation. This highlights the crucial role of collagen XIII in the formation and maintenance
of the NMJ. Our results therefore delineate a myasthenic disorder that is caused by loss-of-function mutations in COL13A1, en-
coding a protein involved in organization of the NMJ, and emphasize the importance of appropriate symptomatic treatment for these
individuals.The neuromuscular junction (NMJ) is a specialized synapse
formed and maintained through interaction of three
main structural components: the motor nerve terminal,
postsynaptic muscle membrane, and synapse-associated
terminal Schwann cells.1 Congenital myasthenic syn-
dromes (CMSs) are inherited disorders of signal transmis-
sion at the NMJ, and they demonstrate considerable
clinical variability and genetic heterogeneity.2 All CMS
types share the clinical feature of fatigable weakness, but
age of onset, manifesting symptoms, distribution of weak-
ness, disease progression, and response to treatment differ
depending on the disrupted molecular mechanism result-
ing from genetic mutations.3 Accurate differential diag-
nosis between the various CMS sub-types and other
congenital neuromuscular conditions remains an impor-
tant clinical need given that CMSs respond symptomati-
cally to appropriate treatment.2,3
CMSs are classified according to the mutated gene and
the resulting pathogenic mechanism, but in general, they
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functions are the most common in that they account
for 88% of CMS-affected individuals in the UK.4 They
most notably occur in RAPSN (CMS type 11 [MIM:
616326 ]), DOK7 (CMS type 10 [MIM: 254300]), and
components of the acetylcholine receptor (AChR;
CMS types 1–4 [see MIM: 601462 for further details]).
Mutations in, for example, COLQ (MIM: 603033) or
CHAT (MIM: 118490)—causing synaptic CMS (CMS type
5 [MIM: 603034]) or presynaptic CMS (CMS type 6
[MIM: 254210]), respectively—are less frequent in that
each accounts for fewer than 10% or 5% of individuals,
respectively,4,5 although this might vary in different
ethnic groups. About 10% of UK individuals with a CMS
have no identified mutation in the known CMS-associated
genes.4 At present, mutations in at least 18 different
genes are known to cause CMSs,1 but a detailed under-
standing of the mechanisms of NMJ formation and matu-
ration remains incomplete. Here, we used whole-exome
sequencing (WES) to identify COL13A1 (MIM: 120350)d Clinical Sciences, University of Leeds, Leeds LS9 7TF, UK; 2Neurosciences
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Table 1. Clinical Features of Individuals with Mutations in COL13A1
Family 1 Family 2
II:1 II:1 II:2
Consanguinity no yes yes
Mutation (type) c.1171delG
(frameshift)
c.5231delG
(splice-site or frameshift)
c.5231delG
(splice-site or frameshift)
Sex female male female
Current age 24 months 27 years died at 8 years
Age at assessment 5 months 24 years 5 years
Age of onset birth birth to 1 year birth
Manifesting symptoms BD, FD ptosis, FD BD, FD
Ptosis þ þ þ
Ophthalmoparesis   left, þright
Facial weakness  þ þ
Bulbar weakness þ  þ
Proximal weakness upper limbs þ  þ
lower limbs þ  þ
Distal weakness upper limbs þ þ þ
lower limbs þ  þ
Axial weakness þ left, þright þ
Distal-joint laxity þ  þ
Contractures   
Spinal rigidity  þ þ
Dysmorphic features þ þ þ
Mild learning difficulties NK þ NK
Decrement on RNS þ þ NA
Abnormal jitter þ þ NA
Other LRTI LRTI CLD, hh, LRTI
Response to treatments DAP, sb, NIV, py-ve none NIV, py-ve
Abbreviations are as follows: BD, breathing difficulty; CLD, chronic lung disease; DAP, 3,4-diaminopyridine; FD, feeding difficulty; hh, hiatus and diaphragmatic
hernia; LRTI, lower-respiratory-tract infection; NA, not assessed; NIV, non-invasive ventilation; NK, not known; py-ve, no response to pyridostigmine treatment;
RNS, repetitive nerve stimulation; and sb, salbutamol.mutations that cause a CMS form that we designate CMS
type 19.
Individual 1 (affected individual II:1 in family 1;
Table 1) is of white European origin. She developed recur-
rent apneas and a poor suck soon after birth, and by
7 months, generalized hypotonia and gastresophageal
reflux were noted. Examination showed mild bilateral
non-fatigable ptosis with normal eye movements and
no facial weakness but also showed poor head control,
marked neck weakness, and limb hypotonia. There
were no joint contractures. When she was 2 years old,
dysmorphic features including low-set ears, microgna-
thia, retrognathia, a high-arched palate, and pectus cari-
natum (barrel chest) were noted. A muscle biopsy from
the quadriceps muscle revealed abnormal variation in
fiber size, and several populations of fibers stained posi-The Americantive for fetal myosin (Figures 1A–1D). Respiratory en-
zymes were normal (Figures 1A–1D), and whole-muscle
MRI was normal. Levels of serum creatine kinase (CK)
were within the normal range. Stimulated single-
fiber electromyography (SFEMG) for the left orbicularis
oculi muscle showed grossly increased jitter (mean
consecutive difference [MCD] ¼ 133.36 5 41.9 ms) and
increased blocking (14%), consistent with a diagnosis
of CMS. Low rates of repetitive nerve stimulation in
the right abductor digiti minimi and left flexor hallucis
brevis showed significant (>20%) decrement at rest
(Figure 1E). There was no response to anticholinesterase
medication. Treatment with 3,4-diaminopyridine (3,4-
DAP; 0.3 mg/kg/day) and salbutamol (0.56 mg/kg/day)
produced a remarkable improvement in her motor and
respiratory function.Journal of Human Genetics 97, 878–885, December 3, 2015 879
Figure 1. Features of Individuals with COL13A1Mutations
(A–D) Muscle biopsy from the quadriceps muscle of affected individual II:1 from family 1 at 6 months of age. (A) H&E staining shows
abnormal variation in fiber size, few central nuclei, and occasional vacant peripheral vacuole-like areas. (B) Staining for NADH-tetrazo-
lium reductase shows occasional fibers with a halo-like appearance. (C) ATPase staining at pH 4.6 shows several populations of fibers
staining positive for fetal myosin. (D) Go¨mo¨ri trichrome staining shows several hypercontracted fibers and enlargedmitochondria. Fiber
size ranges from 4 to 18 mm. Scale bars represent 100 mm.
(E) Repetitive nerve stimulation of left flexor hallucis brevis muscle (II:1 family 1) shows significant (>20%) decrement.Individuals 2 and 3 (affected individuals II:1 and II:2,
respectively, in family 2; Table 1) are siblings with
parental consanguinity and an ethnic origin from the In-
dian subcontinent. Individual 2 had feeding difficulties in
the first year of life and was noted to have ptosis. During
childhood, he had dyspnoea on exertion, recurrent chest
infections, and mild learning difficulties. Neurophysi-
ology was performed when he was 18 years old. Repetitive
nerve stimulation at 3 Hz in the right anconeous muscle
showed a significant (>20%) decrement. SFEMG in
the right extensor digitorum communis showed 50%
increased jitter (mean MCD ¼ 69.8 5 34.4 ms). When
he was 25 years old, examination showed constant
moderate bilateral ptosis (30%), normal eye movements,
mild weakness of eye closure and facial muscles,
and mild weakness of hip extensors. He showed facial
dysmorphism including micrognatia, low-set ears, and a
high-arched palate (Table 1), in addition to skeletal abnor-
malities such as pectus carinatum and marked bilateral
pes cavus. There was no response to treatment with
pyridostigmine.
Individual 3 wasmore severely affected than her brother.
She had severe breathing and feeding difficulties after
birth, partly as a result of a combined hiatus and diaphrag-
matic hernia. A muscle biopsy from the quadriceps muscle
at age 1 year was within normal histological limits. She
depended on oxygen until the age of 2 years and had re-
current chest infections, after which she developed
chronic lung disease. She had delayed motor milestones.
She was predominantly fed with a gastrostomy tube and
had limited tolerance to walking and exercise, which
caused progressive fatigue. Examination at age 5 years
showed bilateral ptosis, mild limitation of eye movements,
and mild facial weakness. Muscle bulk was reduced, and
there was generalized mild muscle weakness. Facial dys-
morphism was similar to that of her brother, individual
2. In addition, pectus carinatum and a degree of spinal ri-880 The American Journal of Human Genetics 97, 878–885, Decembgidity with kyphotic posture, predominantly at the cervi-
cal-thoracic region, were present, but there were no distal
contractures. This individual died at 8 years of age as a
result of severe respiratory problems related to muscle
weakness and her chronic lung disease. Additional clinical
information is presented in the Supplemental Note.
Ethical approval for molecular genetics research studies
and use of data was obtained from the South Yorkshire
Research Ethics Committee (reference no. 11/H1310/1)
and Oxford Research Ethics Committees OXREC B (04/
OXB/017) and OXREC C (09/H0606/74). We obtained
informed consent from all participating families or indi-
viduals. Genomic DNA was extracted from peripheral
venous blood either by standard salt extraction or with a
Nucleon kit (Gen-Probe Life Sciences).
WES was performed with Agilent SureSelect V5 Human
All Exon baits (for individuals I:2 and II:1 in family 1;
Figure 2A) or Roche NimbleGen SeqCap EZ Human Exome
Library v.2.0 (for individual II:1 in family 2) and subse-
quent 100 bp paired-end sequencing on the Illumina
HiSeq platform. Whole-genome alignment of FASTQ
files was performed as described previously.6 We processed
alignments in the SAM and BAM formats with SAMtools,7
Picard, and the Genome Analysis Toolkit (GATK).8,9
Genomic VCFs were generated with the HaplotypeCaller
function of GATK and subsequent joint calling of SNVs
and indels with 217 other locally sequenced samples. Var-
iants were recalibrated as per GATK guidelines,10 although
no hard filtering was performed. The functional conse-
quences of variants were determined with Ensembl’s
Variant Effect Predictor.11 Using in-house-generated Perl
scripts (see Web Resources), we removed variants that
had a minor allele frequency of 1% or higher in dbSNP,
the NHLBI Exome Sequencing Project (ESP) Exome Variant
Server (VCF downloaded May 2014), the Exome Aggrega-
tion Consortium (ExAC) Browser (VCF downloaded
November 2014), and locally sequenced exomes.er 3, 2015
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Figure 2. Sequence Analysis of COL13A1 Mutations and Schematic Representations of COL13A1 and COL13A1
(A) Top: pedigree of affected individual II:1 in family 1. Bottom: IGV pileup of sequencing reads for individual II:1 (blue) and her unaf-
fected mother, I:2 (pink). The red arrow indicates the homozygous frameshift mutation c.1171delG. The mother is heterozygous for this
mutation. Numbers at the top represent physical locations (based on Ensembl genome assembly GRCh37), and nucleotides and amino
acid residues are shown below. Individuals analyzed by WES are indicated by asterisks.
(B) Top: pedigree of affected individuals II:1 and II:2 in family 2. Bottom: IGV pileup of sequencing reads for individual II:1 (pink). The
red arrow indicates the homozygous splice-site mutation c.5231delG.
(C) Schematic of COL13A1, encoding transcript variant 1 (GenBank: NM_001130103.1), in chromosomal region 10q22. Vertical black
bars represent coding exons, and red arrows indicate the locations of pathogenic mutations. Numbers represent physical locations
(Ensembl genome assembly GRCh37).
(D) Schematic of the full-length COL13A1 isoform 1 (GenBank: NP_001123575), including a short intracellular domain, a single trans-
membrane helix (TM; dark gray), and the extracellular region with three collagenous domains (COL1–COL3) separated by short non-
collagenous domains (NC1–NC4). Each collagen domain has separate collagen helix repeats (pink boxes). The approximate location
of the proprotease recognition site is indicated by the black arrow. Numbers indicate the amino acid residues composing each domain.Because both families contain individuals without a
molecular diagnosis of a CMS, we performed a combined
analysis for affected individuals 1 (II:1 in family 1) and
2 (II:1 in family 2) in order to determinewhether they share
a genetic cause of their disease. We processed the variants
that remained after filtering to identify either possible com-
pound-heterozygous or possible homozygous ‘‘functional’’
variants (non-synonymous, splice consensus, or coding
indel variants) with a Combined Annotation Dependent
Depletion (CADD) Phred-like scoreR 10. After this filtering
step, only one candidate gene, COL13A1, remained with
a biallelic pathogenic variant in both families (Table S1).
For individual 1 (II:1 in family 1), we identified a homo-
zygous frameshift variant (c.1171delG [p.Leu392Sfs*71]
[GenBank: NM_001130103.1]) in COL13A1 (Figure 2A).
For individual 2, we identified a homozygous splice-site
mutation, c.5231delG, in COL13A1 (Figure 2B). This
variant is predicted to allow splicing but lead to premature
termination due to a single-base deletion in the codingThe Americansequence (p.Gly175Vfs*20). Neither individual carries pu-
tative ‘‘functional’’ pathogenic variants in other known
CMS-related genes. Sanger sequencing confirmed that indi-
vidual 3 is also homozygous for the c.5231delG splice-site
mutation. Both mutations segregate with the disease in
their respective families (Figure S1) and are absent in the
61,486 individuals of theExACdataset and3,100 ethnically
matched individuals in an in-house dataset. A further 12 in-
dividuals with a genetically undiagnosed but clinically
secure CMS were screened by Sanger sequencing for muta-
tions in COL13A1, but no further putative pathogenic var-
iants were identified.
COL13A1 is a large gene (it is 157 kb in size and has
at least 38 exons; Figure 2C) that is ubiquitously ex-
pressed at low levels in many tissues, including connective
tissues.12–14 It encodes the alpha chain of an atypical,
non-fibrillar transmembrane collagen. COL13A1 (collagen
type XIII alpha1 chain) consists of a short intracellular
domain, a single transmembrane domain that anchors itJournal of Human Genetics 97, 878–885, December 3, 2015 881
to the plasma membrane, and a large, collagenous ectodo-
main (Figure 2D). The extracellular ectodomain contains
three collagenous domains (COL1–COL3) separated by
short non-collagenous domains (NC1–NC4) and a propro-
tease recognition site (Figure 2D), suggesting that the
ectodomain can be proteolytically cleaved and shed into
the extracellular matrix. COL13A1 forms the alpha chain
of collagen XIII, which is trimeric like other collagens,
and is thought to form homotrimers.14,15 Collagen XIII
interacts with fibronectin, heparin, and the basement-
membrane proteins nidogen-2 and perlecan,15 indicating
that it mediates multiple interactions with the extracel-
lular matrix. COL13A1 has been previously implicated in
regulating the maturation of the NMJ16 in either mouse
models lacking the transmembrane anchoring domain17
or Col13a1/ animals.16 Although COL13A1 is present
in the postsynaptic membrane and synaptic basement
membrane and has been postulated as a potential CMS-
associated protein,18 its precise molecular function is
unknown.16
To further understand the localization and potential role
of COL13A1 at the NMJ, we used the quadriceps muscle
biopsy from individual 1 and human laryngeal muscles
from unaffected individuals undergoing therapeutic laryn-
gectomy as controls. Laryngeal muscles have a relatively
small size and high endplate density, which facilitates
visualization of stained endplates. Longitudinal and trans-
verse 8–10 mm sections from fresh-frozen tissues were pro-
cessed for immunofluorescence microscopy via standard
methods. Images were captured on an IX71 Olympus mi-
croscope with Simple PCI software (Digital Pixel Imaging
Systems) and analyzed with Volocity (PerkinElmer) or
captured on a Zeiss LSM 510 inverted confocal microscope.
We used antibodies against synaptophysin (SV2, Develop-
mental Studies Hybridoma Bank, University of Iowa) to
label the presynaptic terminal in NMJs or against S100 cal-
cium-binding protein B (S100b, antibody SAB1402349,
Sigma-Aldrich) to label terminal Schwann cells. We used
Alexa Fluor 488-conjugated fasciculin (Life Technologies)
or Alexa Fluor 488-conjugated a-bungarotoxin and anti-
bodies against DOK7 (H-284, Santa Cruz Biotech) and
MuSK (ab92950, Abcam) to label the intersynaptic space
and key postsynaptic proteins. We used two different
antibodies against the COL13A1 C-terminal region: affin-
ity-purified guinea pig anti-COL13A1 antibody (Eurogen-
tec), against amino acids 442–463 for full-length isoform
1 (GenBank: NP_001123575), or a rabbit polyclonal
antibody (STJ92376, St. John’s Laboratory). The speci-
ficity of the Eurogentec and St. John’s Laboraroty anti-
bodies was verified by immunocytochemical detection
in HEK293 cells overexpressing full-length COL13A1 iso-
form 1 (Figure S2A) and by Western blots (Figure S2B),
respectively. We then demonstrated that COL13A1 local-
ized at the motor endplates in normal control muscle
(Figure 3A) but that COL13A1 was absent in motor end-
plates from individual 1 (affected individual II:1 in family
1), consistent with the effect of the homozygous frame-882 The American Journal of Human Genetics 97, 878–885, Decembshift COL13A1mutation (c.1171del [p.Leu392Sfs*71]) car-
ried by this person (Figure 3B). However, other key
NMJ proteins had normal localization at the motor
endplates from individual 1 (Figure 3C). Western blots on
protein extracts from human muscle, HEK293 cells,
and HEK293 cells overexpressing COL13A1 isoform 1
(GenBank: NP_001123575) as a positive control demon-
strated that endogenous COL31A1 was present in muscle
(Figure S2B), consistent with previous reports.16 However,
the endogenous protein in muscle had a lower apparent
mass than did full-length COL13A1 isoform 1. RT-PCR
confirmed that the endogenous muscle protein was pro-
duced from COL13A1 transcript variant 21 (GenBank:
NM_080798), encoding a smaller protein isoform (Gen-
Bank: NP_542988) (data not shown). Compared to the
major transcript variant 1 (GenBank: NM_001130103.1),
this transcript variant has exons 3, 5, 6 and 30 spliced out.
To determine the effect of COL13A1 loss on endplate
development and NMJ maturation, we engineered the
homologous COL13A1 c.1171delG frameshift mutation
into the immortalized mouse myoblast C2C12 cell
line by using the CRISPR-Cas9 nickase genome-editing
technology according to standard methods.19,20 In brief,
guide oligonucleotides and a repair-template oligonucleo-
tide (Integrated DNA Technologies) were cloned into
an adapted plasmid based on pX335-U6-Chimeric_BB-
CBh-hSpCas9n(D10A),19 a kind gift from Feng Zhang
(Addgene plasmid no. 42335). Guide A oligonucleotide se-
quences were 50-CACCGAGAGATATGGAGCCCCAAAG-30
(forward) and 50-AAACCTTTGGGGCTCCATATCTCTC-30
(reverse), and those for guide B were 50-CACCGTGGCAG
CAAAAACTCACCTT-30 (forward) and 50-AAACAAGGTGA
GTTTTTGCTGCCAC-30 (reverse). The repair template was
50-CAGGGAGAAAAAGGT GATGCTGGCAATGCCATCGG
AGGAGGCAGGGGGGAGCCTGGCCCCCCGGGGTCCC
TGGGCCCCCTGGGCCAAAGGTGAGTTTTTGCTGCCAT
CTGCATTGAGAGAGATATGGAGCCCCAAAGAGTCACAG-
30. C2C12 cells were electroporated with 20 mg of
plasmid and 10 ml repair-template oligonucleotide
(10 mM) with a Neon electroporator (Life Technologies),
selected with 1 mg/ml G418 (Life Technologies), and
cloned by serial dilution in 96-well flat-bottomed culture
plates. We assessed clones by PCR of genomic DNA by
using the primer pair 50-GGTTGACCCAGAAACCCC
AA-30 and 50-ACTTATGACTCCATGCCCAGG-30. Success-
ful mutagenesis was confirmed by the creation of a
new KpnI restriction site and the presence of the dele-
tion after Sanger sequencing.
We then assessed the functional effect of the COL13A1
c.1171delG mutation on AChR clustering after differentia-
tion and fusion of cells intomyotubes and the induction of
AChR clusters by the addition of soluble neural agrin.
AChR clusters were visualized with Alexa Fluor 594-conju-
gated a-bungarotoxin. The c.1171delG mutation caused
the number of AChR clusters longer than 3 mm in differen-
tiated myotubes to be approximately 50% lower than that
in mock transfected (wild-type) or non-transfected C2C12er 3, 2015
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Figure 3. COL13A1 Is Localized at the Human NMJ and Mediates Clustering of AChRs
(A) In human muscle, COL13A1 (red) is enriched at endplate regions of NMJs marked by a-bungarotoxin (Butx; green). Scale bar repre-
sents 10 mm.
(B) Immunofluorescence labeling of quadriceps muscle from individual 1 (affected individual II:1 in family 1), who carries the homo-
zygous frameshift mutation COL13A1 c.1171delG, which causes loss of COL13A1 accumulation (red) at an NMJ marked by a-bungar-
otoxin (Butx; green). Scale bar represents 10 mm.
(C) Normal expression and localization of markers for the NMJ (a-bungarotoxin [Butx]), the presynaptic terminal in NMJs (synaptophy-
sin), terminal Schwann cells (S100b), the intersynaptic space (fasciculin), and postsynaptic proteins (DOK7 and MuSK) in individual 1.
Scale bars represent 10 mm.
(D) AChR-cluster analysis of the COL13A1 c.1171delG variant. Bar graphs show that the frameshift mutation caused the number of
AChR clusters in differentiated mutant myotubes to be statistically significantly lower than that in mock transfected (wild-type) or
non-transfected C2C12 myotubes (left panel), but there was no significant effect on average cluster length (right panel). Statistical an-
alyses used one-way ANOVA with Tukey’s multiple-comparison test (***p < 0.001).myotubes (Figure 3D). The average size of the AChR clus-
ters was not affected (Figure 3D). Effects on postsynaptic
maturation in vivo could come from either muscle-mem-
brane-located COL13A1 or the proteolytically cleaved ec-
todomain of COL13A1. The effect on AChR clustering,
and by implication on the formation and maintenance
of NMJs, appears to be independent of any dramatic effect
in vivo on key AChR-clustering-pathway proteins MuSK
and DOK7 (Figure 3C).
Collagens are known to have important roles at the
NMJ.18Mutations inCOLQ result in an endplate acetylcho-
linesterase deficiency,21 and collagen IV is thought to be
involved in maintaining the integrity of motor nerve ter-
minals.22 Previous studies of either mouse models lacking
the transmembrane anchoring domain17 of Col13a1 or
Col13a1/ animals16 have suggested that COL13A1 has
an essential role in the organization of terminal Schwann
cells and NMJ formation. Mouse models lacking the trans-
membrane anchoring domain exhibit rough and uneven
myofibers, show vacuolization and enlargement of mito-
chondria, and are susceptible to exercise-induced muscle
damage.17 We have not seen any clear evidence of aThe Americanconcomitant myopathy in individuals with COL13A1mu-
tations, given that they all have normal CK levels, normal
fiber-type distributions, and few central nuclei. However,
H&E staining of muscle from individual 1 revealed periph-
eral vacuole-like areas (data not shown), and although an
artifactual effect cannot be ruled out, this is consistent
with observations in knockout animals. Col13a1/
animals grew more slowly than wild-type and heterozy-
gous littermates, such that their general condition deterio-
rated with age. Immunocytochemistry studies showed
defective maturation of the postsynaptic structures, which
is consistent with our in vitro results (Figure 3D). Further-
more, some synaptic sites showed presynaptic defects,
which included incomplete clustering of synaptic vesicles
at nerve terminals. Importantly, nerve terminals did not
always precisely oppose the postsynaptic AChR clusters,
had projections into the synaptic cleft, and were often
erroneously enwrapped by Schwann cells beyond the
postsynaptic specializations. This would cause a decreased
contact surface for neurotransmission. Furthermore,
electrophysiological recordings from the Col13a1/
mice indicated impaired presynaptic function.16 ByJournal of Human Genetics 97, 878–885, December 3, 2015 883
extrapolation from our findings and from the studies of
mouse models, it is likely that the loss of COL13A1
from the synaptic cleft in these individuals affects
both pre- and postsynaptic structural organization and
thus function at the NMJ. A potential interacting partner
on the presynaptic nerve terminal is the intergrin a1 sub-
unit, which acts as a receptor for collagen XIII in cultured
cells.23
In summary, we report human mutations in COL13A1.
Our findings expand the genetic heterogeneity of CMSs
and delineate an unusual form of this condition (CMS
type 19). The phenotypes of the three affected individuals
in this report most closely resemble CMS due to RAPSN
mutations given that onset was at birth and included respi-
ratory and feeding difficulties, slight dysmorphic facial fea-
tures, and ptosis but normal eye movements. However,
they differ from RAPSN-type CMS because of the presence
of pectus carinatum, limited fatigability of the ptosis, and
no beneficial response to anticholinesterase medication.
Accurate molecular testing is essential for the differential
diagnosis of CMS sub-types and other neuromuscular con-
ditions because it can refine treatment and prognosis for
individuals affected by these conditions. We note that
characterization of the CMS for individual 1 prompted
treatment with 3,4-DAP, which blocks voltage-gated potas-
sium channels, and salbutamol, a b2-adrenergic receptor
agonist, which had good clinical effect. The b2-adrenergic
receptor agonists salbutamol and ephedrine have been
found to be beneficial for CMS forms (such as CMS type
10) caused by DOK7 mutations that affect the maturation
and maintenance of NMJ structure, whereas 3,4-DAP en-
hances acetylcholine release from the presynaptic nerve
terminal. The beneficial effects of salbutamol would be
consistent with the fact that COL13A1 mutations affect
the maturation andmaintenance of the synaptic structure,
and the molecular characterization of this condition has
facilitated the implementation of appropriate treatment
strategies. Our results emphasize the crucial role of extra-
cellular-matrix proteins, other than those in the agrin
pathway, in the formation and maintenance of the syn-
apse and highlight the importance of collagen XIII in
NMJ cytoarchitecture and neurotransmission.Supplemental Data
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